Lentiviral transduction of primary myeloma cells to generate anti-myeloma effector T cells.

被引：0
|
作者：
Cignetti, A
Vallario, A
Follenzi, A
Roato, I
Circosta, P
Ghia, P
Naldini, L
Caligaris-Cappio, F
机构：
[1] Univ Turin, Dipartimento Sci Biomed & Oncol Umana, Turin, Italy
[2] Inst Canc Res & Treatment, Lab Canc Immunol, Candiolo, Italy
[3] Inst Canc Res & Treatment, Lab Gene Transfer & Therapy, Candiolo, Italy
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
675
引用
收藏
页码：160A / 160A
页数：1
相关论文
共 50 条
  • [21] Adoptive Therapy with Cord Blood T Regulatory Cells Enhances Anti-Myeloma Efficacy of T Cell Based Immunotherapies
    Nishimoto, Mitsutaka
    Li, Li
    Huang, Meixian
    Lyu, Mi-Ae
    Zeng, Ke
    Ma, Hongbing
    Sadeghi, Tara
    Ahmed, Sairah
    Shah, Nina
    Patel, Krina K.
    Parmar, Simrit
    BLOOD, 2020, 136
  • [22] T cells in myeloma
    Raitakari, M
    Brown, RD
    Gibson, J
    Joshua, DE
    HEMATOLOGICAL ONCOLOGY, 2003, 21 (01) : 33 - 42
  • [23] Functional and molecular analysis of oncogenic pathways in primary myeloma cells.
    Zoellinger, Angela
    Stuehmer, Thorsten
    Sachs, Michael
    Keicher, Christian
    Einsele, Hermann
    Bargou, Ralf C.
    BLOOD, 2006, 108 (11) : 342B - 342B
  • [24] Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment
    Zhou, Jihao
    Shen, Qi
    Lin, Haiqing
    Hu, Lina
    Li, Guoqiang
    Zhang, Xinyou
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (02) : 329 - 336
  • [25] Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells
    Stefka, A. T.
    Park, J-H
    Matsuo, Y.
    Chung, S.
    Nakamura, Y.
    Jakubowiak, A. J.
    Rosebeck, S.
    BLOOD CANCER JOURNAL, 2016, 6 : e460 - e460
  • [26] Induction Of Anti-Myeloma Cellular and Humoral Immunity By Pre-Targeting Clonogenic Myeloma Cells Prior To Stem Cell Transplant With T Cells Armed With Anti-CD3 x Anti-CD20 Bispecific Antibody Leads To Transfer Of Cellular and Hum oral Anti-Myeloma Immunity
    Lum, Lawrence G.
    Thakur, Archana
    Al-Kadhimi, Zaid
    Deol, Abhinav
    Ayash, Lois
    Tomaszewski, Elyse N.
    Yano, Hiroshi
    Schalk, Dana L.
    Kondadasula, Sri Vidya
    Steele, Patricia A.
    Zonder, Jeffrey A.
    Uberti, Joseph P.
    Ratanatharathorn, Voravit
    Abidi, Muneer H.
    BLOOD, 2013, 122 (21)
  • [27] SPECIFIC ANTISERA AGAINST PLASMA CELLS SUPPRESSION OF PLAQUE FORMING CELLS PFC BY ANTI-MYELOMA SERA
    WATANABE, T
    YAGI, Y
    PRESSMAN, D
    FEDERATION PROCEEDINGS, 1971, 30 (02) : A691 - &
  • [28] Anti-idiotypic T cell responses in multiple myeloma using dendritic cells as antigen presenting cells.
    Dabadghao, S
    Bergenbrant, S
    Anton, D
    He, W
    Holm, G
    Yi, Q
    BLOOD, 1997, 90 (10) : 1601 - 1601
  • [29] Bortezomib Is More Effective to Side Population of RPMI8226 Myeloma Cells than Classical Anti-myeloma Agents
    Kim, Kyoung Ha
    Cheong, Hee-Jeong
    Lee, Min Young
    Lee, Namsu
    Lee, Kyu-Taek
    Park, Seong Kyu
    Won, Jong-Ho
    ANTICANCER RESEARCH, 2019, 39 (01) : 127 - 133
  • [30] KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts
    Miki, Hirokazu
    Ozaki, Shuji
    Nakamura, Shingen
    Oda, Asuka
    Amou, Hiroe
    Ikegame, Akishige
    Watanabe, Keiichiro
    Hiasa, Masahiro
    Cui, Qu
    Harada, Takeshi
    Fujii, Shiro
    Nakano, Ayako
    Kagawa, Kumiko
    Takeuchi, Kyoko
    Yata, Ken-ichiro
    Sakai, Akira
    Abe, Masahiro
    Matsumoto, Toshio
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (03) : 328 - 339
12345